For example, vemurafenib (BRAF inhibitor) inhibits melanoma through targeting mutated BRAF, whereas pembrolizumab (anti–PD-1 antibody) blocks the immune checkpoint PD-1 on T cells to increase antitumor immunity. This evidence concerns the gene BRAF and melanoma.